Pfizer Inc PFE

$29.58 +0.14 (0.48%)

Valuation

Market cap
168,596,352,000
Revenue TTM
$62,579,000,000
Net income TTM
$7,771,000,000
PE ratio
9.65
Forward PE
9.99
Profit margin
12.42%
Debt to equity
0.74

Trading

Volume
28,627,400
Avg volume
33,309,836
Day's range
$29.42 – $29.74
Shares out
5,699,674,000
Stochastic %K
89%
Beta
0.32
Analysts
Sell
Price target
$29.45

Price

Company profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under...

Show more

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
212 733 2323
Website
https://www.pfizer.com
Address
66 Hudson Boulevard East, New York, United States

Latest news

Stocktwits

Quantumup Oct 19, 9:35 AM
Citizens maintained $IDYA Market Outperform-$42 ahead of several key presentations coming at ESMO in Madrid (October 23-27). $PFE $NVS REPL MRK ESAIY AMGN AZN ABBV DSNKY ZLAB Citizens said -- IDYA will present updated data for lead compound, darovasertib, for both neoadjuvant and metastatic uveal melanoma. Results from the Phase 2 OptiMUM-01 study in HLA-A*02 positive MUM patients (ESMO 2086P) will be critical and could enable NCCN guideline inclusion of darovasertib in this patient population. Partner Hengrui will present updated Phase 1 data for IDE-849 (SHR-4849) with longer follow-up in Chinese patients (ESMO 3815P).
0 replies
TopOptionAlert Oct 19, 8:06 AM
$PFE NOV06 31C · still actionable Zone: $29.37 to $29.79 Invalidation: close under $28.55 Objectives: $31.40, then $33.10 The math: up 6.2% to the first objective and 11.9% to the second, against 3.5% risk on the invalidation, better than 3 to 1 to the second Think of this swing setup like a quiet neighbor who keeps paying his bills on time while everyone watches the louder houses on the street. Pfizer closed Friday at $29.58, up 4.6 percent in five sessions, and buyers held the $29.42 low on both Thursday and Friday, which tells you demand showed up right under price, not far below it. Earnings on November 3 give this move a clear date to work toward, and a close over the $29.88 high would mean buyers are willing to pay a new yearly high for that report. If price closes under $28.55 the quiet strength story is wrong and you step aside, plain and simple. P.S. Watch $29.88 on Monday. It is the highest price buyers have paid in a year, and clearing it changes the conversation from recovery to breakout.
0 replies
thatsolardude365 Oct 19, 7:16 AM
$PFE: third-party payors are the other side of Chantix. Health plans and insurers that paid or reimbursed for Pfizer-brand Chantix Sept 2015 to Sept 2021 draw pro rata from the rest of the $44M fund. Claims closed. Open Class Actions.
0 replies
RallyRocket Oct 18, 5:45 PM
$PFE think there’s a little more to this story.
0 replies
INEEDMONEY87 Oct 18, 1:42 PM
$PFE i want $24 again
1 replies
DrMcSavage Oct 18, 12:40 AM
$PFE I don’t expect a Moderna type move but it can be significant
1 replies
zustrelaax Oct 17, 7:53 PM
$PFE $NVAX IDWeek 2026 runs Oct 21–24, and Pfizer is presenting 57 abstracts there, including 12 oral presentations with clinical milestones for its next-gen pediatric pneumococcal vaccine and registrational Lyme vaccine. Positive readouts would be a genuine catalyst. Any surprisre announcements will move it to the 35
3 replies
Samishere Oct 17, 4:17 PM 1 replies